Nutriband Inc. (NTRBW)
Nutriband Inc.
121 South Orange Avenue
Suite 1500
Orlando, FL 32801
United States
407 377 6695
https://www.nutriband.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | 175k | N/D | 1974 |
| Mr. Gareth Sheridan | Founder, CEO & Director | 175k | N/D | 1990 |
| Mr. Gerald Goodman | CFO & Chief Accounting Officer | 140k | N/D | 1948 |
| Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics | 159k | N/D | 1966 |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer | N/D | N/D | 1970 |
| Mr. Michael Myer | President of Pocono Pharmaceutical | 40.6k | N/D | 1985 |
| Mr. Tyler Overk | Head of Active Intelligence | N/D | N/D | 1984 |
Descripción
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Nutriband Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
